Trueblood Wealth Management LLC Has $811,000 Position in Danaher Co. (NYSE:DHR)

Trueblood Wealth Management LLC grew its position in Danaher Co. (NYSE:DHR) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,532 shares of the conglomerate’s stock after purchasing an additional 150 shares during the period. Trueblood Wealth Management LLC’s holdings in Danaher were worth $811,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new position in Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the 3rd quarter valued at about $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher during the 3rd quarter worth approximately $55,000. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DHR has been the subject of several research reports. Guggenheim initiated coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. Royal Bank of Canada dropped their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research report on Friday, December 13th. Finally, Barclays reduced their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Stock Down 1.4 %

DHR stock opened at $238.41 on Monday. The business’s 50 day simple moving average is $234.85 and its 200 day simple moving average is $253.42. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The firm has a market capitalization of $172.20 billion, a PE ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.02 earnings per share. As a group, research analysts anticipate that Danaher Co. will post 7.49 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s payout ratio is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.